以上内容来自Benzinga Earnings专栏,原文如下:
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly sales of $99.430 million which beat the analyst consensus estimate of $96.606 million by 2.92 percent. This is a 42.95 percent increase over sales of $69.554 million the same period last year.